RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$12.99
+3.51% today
Updated 2026-04-29
Market cap
$201.54M
P/E ratio
—
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
—
52W range
$12 – $17
Volume
1.5M
Atrium Therapeutics, Inc. Common Stock (RNA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-265.90%
Operating margin
-3,388.00%
ROE
-44.00%
ROA
-399.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $11.27M | — | — | — | — |
| 2012 | $10.36M | — | — | — | — |
| 2013 | $13.09M | — | — | — | — |
| 2018 | $379000.00 | $-11.93M | -2,125.86% | -2,769.92% | -3,148.81% |
| 2019 | $2.32M | $-24.73M | 100.00% | -747.39% | -1,066.58% |
| 2020 | $6.79M | $-43.98M | 100.00% | -652.38% | -648.03% |
| 2021 | $9.33M | $-117.37M | 100.00% | -1,265.83% | -1,258.52% |
| 2022 | $9.22M | $-169.08M | 100.00% | -1,939.65% | -1,833.01% |
| 2023 | $9.56M | $-212.22M | 78.02% | -2,464.41% | -2,219.87% |
| 2024 | $10.90M | $-322.30M | 100.00% | -3,477.43% | -2,957.71% |
| 2025 | $18.62M | $-76.68M | 100.00% | -412.58% | -411.88% |